Immunic (IMUX) Stock Price, Quote, News & History | Benzinga

SPY—QQQ707.87−0.27%BTC/USD—DIA—GLD—TLT80.06+0.01%

Immunic Inc (IMUX) Stock Price, Quote, News & History

IMUXNASDAQ

Trade with Public

Trade with Public

$6.97

-0.13-1.83%

Last update: Oct 16, 6:24 PM

$6.87

-0.23-3.29%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$7.10

Close

$6.97

Volume / Avg.

366.85K / 295.87K

Day Range

$6.80 - $7.92

52 Wk Range

5.06 - 17.43

Market Cap

$93.69M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

22

Short Interest

16.1%

Days to Cover

4.56

Recent Immunic, Inc. News

EXCLUSIVE: Immunic Appoints Former Genentech Exec Erik Lundgren As CEO

Immunic (IMUX) stock rises premarket to $13.14 as the company names former Genentech executive Erik Lundgren as CEO. See how his historic multiple sclerosis drug launch experience accelerates Immunic's Phase 3 trials in 2026.

Anusuya Lahiri

Amazon To Rally More Than 26%? Here Are 10 Top Analyst Forecasts For Thursday

Top Wall Street analysts changed their outlook on top names. See all rating changes at https://www.benzinga.com/analyst-stock-ratings

Avi Kapoor

Immunic Appoints New Medical Officer To Lead Clinical And Regulatory Strategy

Immunic appoints Michael Panzara as CMO, granting inducement equity award as he takes charge of clinical and regulatory strategy.

Vandana Singh

Immunic's Next-Gen Oral Multiple Sclerosis Drug Poised To Capture Share, Analyst Says

Stifel initiates coverage on Immunic (IMUX) with a Buy rating. Analysts see potential for VidoCa to disrupt the MS market via better safety.

Vandana Singh

This Parsons Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Top Wall Street analysts changed outlook on top names. See all rating changes at https://www.benzinga.com/analyst-stock-ratings and analysts' views on PSN.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-87.72M

Investing Cash Flow (TTM)

-329.00K

Financing Cash Flow (TTM)

188.82M

Free Cash Flow (TTM)

-88.05M

Capital Expenditure (TTM)

-329.00K

Net Change in Cash (TTM)

100.77M

Analyst Trends and Forecast

1

Apr

1

May

1

Aug

2

Sep

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.2

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

-$59.97M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

0.76

Earnings Yield % (TTM)

-50.21%

Earnings Yield % (FWD)

-37.62%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$9.35

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$155.10M

Debt to Equity

0.00

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-